Uterine Fibroids in Black Women

A uterine fibroid is a benign muscular growth in the wall of the uterus. It is not cancer, and it is extremely common. What differs by race is not whether fibroids happen but when they start, how many there are, how badly they hurt, and what happens after a woman reports them. Stewart and colleagues reviewed 60 publications in BJOG and found that Black race was the only factor recurrently reported to raise fibroid risk, at two to three times the risk in White women. This guide covers that finding and the reproductive-health silo around it: symptoms, the treatment gap, the relaxer question, pregnancy, and endometriosis.

How common are fibroids in Black women, and how young do they start?

Common, and young. The best-known estimate is that over 80 percent of Black women and nearly 70 percent of White women develop fibroids by age 50. The more useful finding is the early one: ultrasound screening of asymptomatic women aged 18 to 30 found fibroids in 26 percent of Black women and 7 percent of White women.

That early-onset number is the part almost no competing page reports, and it changes what a reader in her twenties should do with a heavy period. Marsh and colleagues published the 18-to-30 ultrasound finding in Fertility and Sterility, in women who had never been pregnant and had no symptoms. The NIEHS Study of Environment, Lifestyle and Fibroids screened Black women aged 23 to 34 who had never been told they had a fibroid, and the enrollment ultrasound found fibroids in 23.3 percent of them. Nearly one in four had a fibroid nobody had mentioned.

The 80 percent figure deserves a caveat that is almost always dropped. It comes from Baird and colleagues in the American Journal of Obstetrics and Gynecology, the paper reports an odds ratio of 2.9 (95 percent CI 2.5 to 3.4), and the authors never give precise percentages. The screening was done in a single urban health-plan population in the mid-1990s. It is a strong finding and a narrow sample, and quoting it as a current national statistic overstates what was measured. How that distinction is handled here is described in how we research.

How long do Black women wait for a fibroid diagnosis?

Nobody publishing this page can tell you, and the honest answer matters more than a confident one. The claim that Black women wait years longer for a fibroid diagnosis is repeated constantly across health media. When this was last checked, no verifiable US figure for average age at fibroid diagnosis, or for length of diagnostic delay, could be sourced to a primary document.

That absence is itself informative. The screening studies above show fibroids present in Black women in their twenties and early thirties who had never been told, so the raw material for a delay is clearly there. What does not exist, as far as this site could verify, is a national dataset measuring the gap between onset and diagnosis by race.

The practical consequence is unchanged. A woman in her twenties with heavy bleeding, pelvic pressure or anemia has a real reason to ask specifically whether fibroids have been ruled out, rather than waiting for a clinician to raise it. Pages that quote a specific delay figure without a source are guessing, and this one will not.

What do fibroid symptoms actually feel like, and is the disease itself different?

Fibroids commonly cause heavy or prolonged menstrual bleeding, pelvic pressure or fullness, back and leg discomfort, frequent urination, and the fatigue that follows blood loss. In Black women the disease itself is measurably larger. In a trial subgroup, Black participants had 7.3 fibroids at baseline against 3.7 in White participants.

Berman and colleagues reported that baseline difference in the Journal of Women’s Health from the LAP-RFA trial, at P less than or equal to 0.001, alongside worse symptom severity scores and worse fibroid-related quality of life. Roughly twice the tumor count, and the symptom scores track it.

This reframes a conversation many women have had. Heavy bleeding described as normal for you is often a larger tumor burden producing a proportionally larger symptom load. Anemia from chronic heavy bleeding is a measurable finding, not an impression, and it is worth asking for the blood count that shows it.

Why do Black women get more fibroid surgery and less fibroid treatment?

Because both are true in different datasets, and the contradiction is the finding. Wechter and colleagues, using National Inpatient Sample data, reported a relative risk for Black versus White women of 3.5 for fibroid-related hospitalization, 2.4 for hysterectomy and 6.8 for myomectomy. More surgery, by a wide margin.

Then a Veterans Affairs study of 8,247 veterans with symptomatic fibroids and anemia found the opposite pattern for treatment overall. Black veterans were less likely to receive any treatment at all, by 10.3 percentage points among those under 45 and 20.3 percentage points among those aged 45 and over. Not less likely to receive one specific procedure. Less likely to be treated.

Say the two plainly and they stop contradicting each other. In the inpatient data, Black women who reach an operating room are disproportionately represented, which is consistent with later presentation and heavier disease. In the VA data, a documented, symptomatic, anemic population still went untreated more often. The failure is not that surgery is offered too much or too little. It is that the decision arrives late and the menu arrives incomplete.

What should you actually ask for at a fibroid appointment?

Ask for the full range of options in writing, and treat a single-option consultation as a reason for a second opinion. That is the position this site takes on the treatment-disparity data. It is not a recommendation for or against any procedure, because that decision depends on an examination, your imaging, your anemia status and whether you want a future pregnancy.

Four requests are reasonable to make of any clinician, and none of them require medical knowledge to ask:

1. Ask what all the options are, including doing nothing for now. Then ask which ones were considered and set aside for you specifically, and why.
2. Ask what this decision does to future fertility, and say out loud whether that matters to you, before options get narrowed on your behalf.
3. Ask for the numbers. Fibroid count, size, location, and your hemoglobin or ferritin if bleeding has been heavy. These belong to you and they travel with you.
4. Ask what happens if you wait three months, and what would change the answer. A clinician who cannot describe the watch-and-wait path is describing only one path.

A second opinion is not an accusation and it does not require a complaint. It exists to test whether a recommendation is the only reasonable one, which is exactly the question the disparity data raises.

Do hair relaxers cause fibroids?

Not supported by the evidence. The NIEHS analysis of 4,162 Black women found no significant association at any level of exposure. Straightener use at ages 10 to 13 gave an odds ratio of 1.15 (95 percent CI 0.96 to 1.36), frequent use 1.18 (0.99 to 1.42), and incident fibroids a hazard ratio of 1.14 (0.81 to 1.63).

Every one of those confidence intervals crosses 1, which means the data cannot distinguish the result from no effect at all. The detail that settles it is comparative: the same NIEHS analysis found a similar association in White women, odds ratio 1.23, in a group where 5 percent or fewer used straighteners. An exposure that shows the same signal in a population that barely has the exposure is not explaining the disease.

This matters because the relaxer question absorbs enormous attention that the treatment gap deserves. The uterine cancer research is a separate question with a genuinely different answer, and it is handled in full on hair relaxers and fibroids, including what that study did and did not measure.

How much more dangerous is pregnancy for Black women in the US?

Substantially, and the gap is in the outcomes that hypertension drives. NCHS reports maternal mortality at 44.8 deaths per 100,000 live births for Black non-Hispanic women against 14.2 for White non-Hispanic women. Any hypertensive disorder in pregnancy occurs in 20.9 percent of Black delivery hospitalizations versus 14.7 percent of White ones.

Two things about that mortality figure. It has fallen sharply from its pandemic-era peak, and the peak number, 69.9 per 100,000, still circulates widely as though it were current. It is not. The trajectory in the table below is the whole picture, and the current rate is still more than three times the White rate.

The pressure-related numbers are moving the wrong way. NCHS reports gestational hypertension at 12.3 percent for Black non-Hispanic mothers against 11.3 percent for White non-Hispanic mothers, and a 66 percent rise for Black mothers since the baseline year noted in the table below. Preterm birth runs at 14.86 percent for Black non-Hispanic mothers against 9.49 percent for White, on a national rate of 10.41 percent. This is why the blood-pressure work described in high blood pressure in Black women is reproductive health, not a separate topic, and why the same logic applies to type 2 diabetes in Black women.

Are Black women less likely to have endometriosis, or less likely to be diagnosed?

Diagnosed. That distinction is the entire finding. A systematic review by Bougie and colleagues in BJOG reported that Black women were about half as likely as White women to receive an endometriosis diagnosis, with an odds ratio of 0.49 (95 percent CI 0.29 to 0.83). Diagnosis rates are not incidence rates.

Two cautions belong with that number. The review reported high heterogeneity, meaning the pooled studies disagreed considerably, so the odds ratio summarizes an inconsistent literature rather than settling it. And a diagnosis odds ratio measures the health system, not the uterus.

Whether Black women get endometriosis less often is not something this review can answer. What it does say is that pelvic pain in a Black woman is less likely to end in this particular diagnosis, which is a reason to ask directly whether endometriosis has been considered.

Common questions about fibroids in Black women

Do 80 percent of Black women really get fibroids?

The figure is real but often misquoted. Baird reported cumulative incidence of over 80 percent by age 50 in Black women and nearly 70 percent in White women, from one urban health-plan sample screened in the mid-1990s. It is not a current national statistic.

Can fibroids start in your twenties?

Yes, and often without symptoms. Ultrasound found fibroids in 26 percent of asymptomatic Black women aged 18 to 30, and in 23.3 percent of Black women aged 23 to 34 in the NIEHS SELF cohort who had never been given a diagnosis.

Should I stop using relaxers to prevent fibroids?

The fibroid evidence does not support that reasoning. In the NIEHS analysis of 4,162 Black women, every confidence interval for straightener use crossed 1, and a similar association appeared in White women who barely used straighteners.

Does having fibroids mean I will need a hysterectomy?

No. Fibroid management ranges from monitoring to medication to several procedures, and the right path depends on your imaging, symptoms, anemia and fertility plans. Ask for the full list of options and what each does to future pregnancy.

Why do Black women have more fibroid surgery but less treatment overall?

Different datasets measure different points. Inpatient data shows more surgery once women reach hospital, while a VA study of symptomatic, anemic patients found Black veterans less likely to receive any treatment. Both point to late, narrow decisions.

Sources

• Baird DD et al., High cumulative incidence of uterine leiomyoma in black and white women, Am J Obstet Gynecol. Screening mid-1990s, published 2003. Checked when this page was last reviewed.
• Marsh EE et al., Burden, prevalence, and treatment of uterine fibroids in young women, Fertility and Sterility. Published 2013. Checked when this page was last reviewed.
• Harmon QE et al., NIEHS Study of Environment, Lifestyle and Fibroids, PLoS One. Enrolled 2010-2012. Checked when this page was last reviewed.
• Stewart EA et al., Epidemiology of uterine fibroids: a systematic review, BJOG. Published 2017. Checked when this page was last reviewed.
• Wechter ME et al., Complications in hysterectomy and myomectomy for leiomyoma, Am J Obstet Gynecol. 2007 National Inpatient Sample. Checked when this page was last reviewed.
• VA HSR&D, Racial differences in treatment of symptomatic fibroids with anemia, Women’s Health Issues. FY2010-FY2018. Checked when this page was last reviewed.
• Berman JM et al., Racial disparities in fibroid burden and outcomes, Journal of Women’s Health. LAP-RFA trial. Checked when this page was last reviewed.
• NIEHS Sister Study, Hair straightener use and uterine fibroids. Published 2025. Checked when this page was last reviewed.
• NCHS, Maternal Mortality Rates in the United States, Health E-Stat 113. 2024 data. Checked when this page was last reviewed.
• CDC, Hypertensive disorders in pregnancy among delivery hospitalizations, MMWR 2022;71:585-591. 2017-2019. Checked when this page was last reviewed.
• NCHS, Births: Final Data, National Vital Statistics Reports 75-4. 2024. Checked when this page was last reviewed.
• NCHS, Births: Provisional Data, National Vital Statistics Reports 75-2. 2024. Checked when this page was last reviewed.
• Bougie O et al., Influence of race on endometriosis diagnosis: systematic review and meta-analysis, BJOG. Published 2019. Checked when this page was last reviewed.